Leslie Worona
Family · New York, NYNPI 1548576457
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (55.0%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. Fennec Pharmaceuticals, Inc. accounts for 64.5% of it on its own, with 20 other manufacturers making up the rest. 2025 is the largest year on record at $52,590, more than ten times the $73 reported in 2021. Among family clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 268 payments — averaging $285.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Fennec Pharmaceuticals, Inc.$49K
- Merck$22K
- Genmab U.S., Inc.$798
- Coherus Oncology, Inc.$740
- Napo Pharmaceuticals Inc$505
- Blueprint Medicines Corporation$464
- plus $2K from 15 others
What the payments were for
- Consulting fees$42,16555%
- Speaking & faculty fees$10,42514%
- Travel & lodging$14,31819%
- Food & beverage$9,68713%
- Education$260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Fennec Pharmaceuticals, Inc. | 38 | $49,407 |
| Merck | 62 | $22,461 |
| Genmab U.S., Inc. | 33 | $798 |
| Coherus Oncology, Inc. | 12 | $740 |
| Napo Pharmaceuticals Inc | 11 | $505 |
| Blueprint Medicines Corporation | 13 | $464 |
| GSK | 16 | $405 |
| Novartis | 21 | $362 |
| Eisai Inc. | 13 | $281 |
| Regeneron Healthcare Solutions, Inc. | 12 | $261 |
| Bayer | 11 | $222 |
| Caris MPI, Inc. | 7 | $186 |
| Syndax Pharmaceuticals, Inc. | 1 | $144 |
| Tempus AI, Inc | 5 | $137 |
| Amgen | 5 | $94 |
| IBSA Pharma Inc. | 2 | $35 |
| Beone Medicines USA, Inc. | 2 | $33 |
| Rigel Pharmaceuticals, Inc. | 1 | $25 |
| Foundation Medicine, Inc. | 1 | $24 |
| Beigene USA, Inc. | 1 | $20 |
| AstraZeneca | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$76,622 in reported general payments places this provider in the 95th percentile of 8,883 family providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pantoprazole Sodium | 46 | $135 |
| Ondansetron OdtOndansetron | 29 | $123 |
Paid to pharmacies, not to this prescriber.
Other family in New York
- Christina NalboneNew York$197K
- Casey GrilloNew York$191K
- Mary Sullivan-WhalenNew York$137K
- Thomas SaglimbeniNew York$48K
- Kathryn JohnsonNew York$48K
- Derek PinedaNew York$38K
- Rebecca SchoriNew York$32K
- Evangelia NezisNew York$22K
- Colette NelsonNew York$21K
- Margaret CuomoNew York$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.